 Connection
Wells Messersmith to Lung Neoplasms
This is a "connection" page, showing publications Wells Messersmith has written about Lung Neoplasms.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.268 |
|
|
|
-
Stuart CM, Kirsch MJ, Zhuang Y, Meguid CL, Sugawara T, Colborn KL, Messersmith W, Lieu C, Gleisner AL, Del Chiaro M, Schulick RD, Meguid RA. Pulmonary metastasectomy is associated with survival after lung-only recurrence in pancreatic cancer. Surgery. 2023 09; 174(3):654-659.
Score: 0.090
-
Bardia A, Messersmith WA, Kio EA, Berlin JD, Vahdat L, Masters GA, Moroose R, Santin AD, Kalinsky K, Picozzi V, O'Shaughnessy J, Gray JE, Komiya T, Lang JM, Chang JC, Starodub A, Goldenberg DM, Sharkey RM, Maliakal P, Hong Q, Wegener WA, Goswami T, Ocean AJ. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial. Ann Oncol. 2021 06; 32(6):746-756.
Score: 0.077
-
Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. J Clin Oncol. 2017 Aug 20; 35(24):2790-2797.
Score: 0.059
-
Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Invest New Drugs. 2013 Feb; 31(1):115-25.
Score: 0.041
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|